openPR Logo
Press release

HIV Reservoirs Cure Initiative to Meet in Boston at CROI 2011

02-14-2011 03:13 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Hiv-Workshop

A research team will meet at the end of February in Boston where the 18th Conference on Retroviruses and Opportunistic Infections (CROI) will be held, to work on a strategic research plan for an HIV cure and prepare the program of the 5th edition of the 'HIV Persistence, Reservoirs & Eradication Workshop'.

Toulon, France, February 14, 2011 -- Dr Alain Lafeuillade, MD, PhD -a French doctor and researcher working on HIV Reservoirs- launched in 2003 the first international workshop on HIV persistence during therapy. Together with an international team of scientists, they are addressing the reasons why HIV persists in treated individuals, the so called 'HIV reservoirs'. In order to achieve a HIV cure one day, researchers have to understand how this reservoir is established and how it is maintained.

This research team will meet at the end of the month in Boston where the 18th Conference on Retroviruses and Opportunistic Infections (CROI) is to be held. They will work on a strategic research plan and prepare the program of the 5th edition of their workshop in December 2011.

“With this multi-disciplinary working group, I am confident that we will bring patients better therapeutic strategies in a near future” told Doctor Alain Lafeuillade, Head of Department of Infectious Diseases in France and coordinator of this initiative. “Our main force is to promote innovative ideas outside the beaten tracks”, he added.

Members of the press and/or other interested parties may also obtain more information by contacting the following: Alain Lafeuillade MD, PhD, Chief Department of Infectious Diseases, General Hospital, Toulon, France Chair of the International Workshop on HIV Persistence, Reservoirs & Eradication Strategies; Ph: +33-4-94616340 ; http://www.hiv-eradication.org

Contact:
Alain Lafeuillade
Hiv-Workshop
Chief Department of Infectious Diseases, General Hospital
Toulon, France
+33-494616340
lafeuillade@orange.fr
http://www.hiv-workshop.com

Members of the press and/or other interested parties may also obtain more information by contacting the following: Alain Lafeuillade MD, PhD, Chief Department of Infectious Diseases, General Hospital, Toulon, France Chair of the International Workshop on HIV Persistence, Reservoirs & Eradication Strategies; Ph: +33-4-94616340 ; http://www.hiv-eradication.org

Contact:
Alain Lafeuillade
Hiv-Workshop
Chief Department of Infectious Diseases, General Hospital
Toulon, France
+33-494616340
lafeuillade@orange.fr
http://www.hiv-workshop.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HIV Reservoirs Cure Initiative to Meet in Boston at CROI 2011 here

News-ID: 162358 • Views: 864

More Releases from Hiv-Workshop

Scientific Strategy Towards HIV Reservoirs Cure
The Fifth 'International Workshop on HIV Persistence, Reservoirs & Eradication Strategies' will be held from December 6-9, 2011, in St. Martin, West Indies. The topics explored are geared towards an understanding both of the mechanisms involved in HIV persistence in its reservoirs, and the possibilities of finding new strategies to use in order to eradicate HIV from infected hosts. The preliminary program is now online. Toulon, France, April 05, 2011 --

More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral